Understanding Mezigdomide: Mechanism of Action and Early Clinical Development
Key Points
- Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) that acts as a potent targeted protein degrader.
- The agent induces degradation of Ikaros and Aiolos, resulting in both direct antimyeloma activity and immune activation.
- Early-phase studies demonstrated meaningful activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated and triple-class refractory, including those with extramedullary disease and prior B-cell maturation antigen exposure.
- Neutropenia is the most common adverse event but can be effectively managed with proactive growth factor support.
At a Rapid Reactions discussion coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, spoke with Paul Richardson, MD, of Dana-Farber Cancer Institute, about the development of mezigdomide and the emerging data supporting its use in relapsed/refractory multiple myeloma. Dr. Richardson emphasized that the oral CELMoD was specifically designed with community practice in mind, combining potent antimyeloma activity with a manageable safety profile that can be readily incorporated into routine care.
The discussion highlighted the unique mechanism of action of mezigdomide. Unlike earlier immunomodulatory agents, mezigdomide functions as a highly potent cereblon E3 ligase modulator, driving targeted degradation of the transcription factors Ikaros and Aiolos. This process not only induces myeloma cell death but also enhances immune activation, contributing to the drug’s broad activity across multiple disease settings.
Dr. Richardson reviewed findings from early clinical development, noting that phase 1 studies established a once-daily 1-mg dose administered on a 3-weeks-on, 1-week-off schedule. In heavily pretreated patients, mezigdomide monotherapy produced an overall response rate of approximately 41%, while responses were also observed in traditionally difficult-to-treat populations, including patients with extramedullary disease and those previously exposed to B-cell maturation antigen-directed therapies.
Additional studies evaluating mezigdomide in combination regimens demonstrated substantial synergy with several established myeloma therapies. Response rates generally ranged from 75% to 90% when paired with agents such as carfilzomib, daratumumab, or elotuzumab, supporting continued development of mezigdomide-based combinations and laying the groundwork for the phase 3 SUCCESSOR program.